Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3393 | Rosuvastatin (Inhibitor arm) Wiki | 0.58 |
| drug1363 | Electronic survey Wiki | 0.58 |
| drug3394 | Rosuvastatin (Placebo arm) Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D008173 | Lung Diseases, Obstructive NIH | 0.15 |
| D029424 | Pulmonary Disease, Chronic Obstructive NIH | 0.15 |
| D012141 | Respiratory Tract Infections NIH | 0.09 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0006536 | Pulmonary obstruction HPO | 0.15 |
| HP:0006510 | Chronic pulmonary obstruction HPO | 0.15 |
| HP:0011947 | Respiratory tract infection HPO | 0.09 |
Navigate: Correlations HPO
There are 3 clinical trials
This study evaluates the performance of ColdZyme® mouth spray on prevention and alleviation of induced rhinovirus upper respiratory tract infection in healthy volunteers. Half of participants will receive ColdZyme® mouth spray while the other half will receive placebo.
Description: Reduction in viral load in the URT(Upper Respiratory Tract), after challenge with rhinovirus, in relation to placebo
Measure: Reduction in viral load in the URT Time: 7 daysDescription: Reduction of number of days having a total symptom severity score of 6 or higher using a 5-graded Jackson scale, in relation to placebo.
Measure: Prevention of symptomatic URTI (Upper Respiratory Tract Infection) Time: 11 daysDescription: Asymptomatic URTI will be assessed by quantification of viral load at peak day (day with highest viral load measured by oropharyngeal swab).
Measure: Prevention of asymptomatic URTI. Time: 11 daysDescription: The number of days with cold is defined as the sum of all days with a total score of ≥ 6 according to the modified method of Jackson.
Measure: Fewer days with symptomatic URTI Time: 11 daysDescription: The number of days with asymptomatic URTI is defined as the sum of all days with a viral load significantly different from the baseline.
Measure: Fewer days with asymptomatic URTI. Time: 11 daysDescription: Nasal samples will be analysed for the quantity of IL-6 (Interleukin 6), IL-8 and IFNα (Interferon alpha).
Measure: Lower level of proinflammatory proteins Time: 11 daysAn open access study that will define and collect digital measures of coughing in multiple populations and public spaces using various means of audio data collection.
Description: Size of collected audio dataset measured as number of collected cough sounds, targeting ≥10,000 identified coughs.
Measure: Dataset size Time: 14 daysDescription: Identification of cough sounds by the existing mathematical model with ≥ 99% specificity and ≥ 60% sensitivity
Measure: Cough sound identification Time: 14 daysDescription: Increase in the sensitivity of the mathematical model to cough sounds to ≥ 70% while retaining the specificity of ≥ 99%
Measure: Improvement of the existing model Time: 14 daysDescription: Determination of the level of acceptance and satisfaction of the solution by patients by means of a Standard Usability Questionnaire to provide feedback. The score ranges from 10 to 50, higher score indicating a better usability.
Measure: Evaluate the usability of the application Time: 14 daysColdamaris lozenges are a medical device containing 10 mg carrageenan/lozenge. The goal of the study is to determine whether the iota-carrageenan content in the saliva of subjects who sucked Coldamaris® lozenges is sufficient to inhibit the replication of 4 of the most common respiratory viruses causing common cold. At least 29 subjects will be screened, in order to get 24 subjects included.
Description: The mean iota-carrageenan concentration in saliva during sucking an iota-carrageenan containing lozenge should reach published IC90 values for 2 human rhinoviruses.
Measure: The primary outcome measure is the iota-carrageenan concentration in saliva. Time: 3 monthsDescription: Iota-carrageenan concentration in saliva of subjects should be high enough to inhibit replication of human rhinoviruses, human Coronavirus OC43, human influenzavirus H1N1n, and Coxsackievirus A10.
Measure: The secondary outcome measure is the iota-carrageenan concetration in salvia. Time: 3 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports